LALindsay N. Alfano

Lindsay N. Alfano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lindsay N. Alfano has a total of 850 co-authors. Here are the top co-authors by number of shared publications:

  • Linda Pax Lowes

    Nationwide Children's Hospital, Columbus, OH

    47 shared publications
  • Jerry R. Mendell

    The Abigail Wexner Research Institute at Nationwide Children's Hospital, Center for Gene Therapy, Columbus, Ohio; The Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; The Department of Neurology, Wexner Medical Center at The Ohio State University, Columbus, Ohio

    16 shared publications
  • Kevin M. Flanigan

    Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA

    15 shared publications
  • Megan Iammarino

    Jerry Mendell Center for Gene Therapy, Nationwide Children's Hospital Columbus Ohio USA

    15 shared publications
  • Jerry R. Mendell

    Center for Gene Therapy, Nationwide Children’s Hospital, Columbus, USA

    13 shared publications
  • Linda P. Lowes

    Jerry R. Mendell Center for Gene Therapy The Abigail Wexner Research Institute at Nationwide Children's Hospital Columbus Ohio USA

    11 shared publications

Latest Publications

  • Open Access

    Natural History of Limb Girdle Muscular Dystrophy D1 (LGMDD1)

    by Andrew R. Findlay, Stephanie M. Hunn, Aileen S. Jones, Amanda Butler, Sandhya Sasidharan, Melissa Hayes, Jeffrey M. Statland, Talia Strahler, Robert Will, Matthew P. Wicklund, et al.

    Background and ObjectivesLimb‐girdle muscular dystrophy type D1 (LGMDD1) is caused by dominantly inherited pathogenic variants in DNAJB6, a cochaperone of HSP70. Prior work has described the clinic...

  • Open Access

    Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study

    by Jerry R. Mendell, Zarife Sahenk, Linda P. Lowes, Megan A. Iammarino, Lindsay N. Alfano, Craig M. McDonald, James E. Signorovitch, Jim Jin, Jing Li, Stefanie Mason, et al.

    Aims: We report 5‐year results from a phase 1/2a study of delandistrogene moxeparvovec, a recombinant adeno‐associated virus serotype rh74 vector‐based gene therapy for Duchenne muscular dystrophy (DMD), with post hoc analyses contextualizing functional outcomes. Methods: Four ambulatory patients with DMD (≥ 4–< 8 years at enrollment) entered an open‐label trial (Study 101; NCT03375164), receiving a single intravenous dose of delandistrogene moxeparvovec (2.0 × 10 14 vg/kg by supercoiled quantitative polymerase chain reaction (qPCR), equivalent to 1.33 × 10 14 vg/kg by linear qPCR). Safety and functional outcomes (including North Star Ambulatory Assessment [NSAA] total score, time to rise [TTR] from floor, 10‐m walk/run [10MWR] time) were assessed. In post hoc analyses, functional outcomes of delandistrogene moxeparvovec–treated patients were compared with propensity‐score‐weighted external controls (ECs) and natural history predictions. Results: No new safety signals were reported 5 years post‐infusion. One patient had cardiomyopathy at year 5; however, this event was deemed unrelated to treatment. All delandistrogene moxeparvovec–treated patients (mean age, 10.2 years) remained ambulant. The 5‐year NSAA total score mean change from baseline (standard deviation) for treated patients versus ECs was +7.5 (2.4) versus −3.9 (2.9) (least‐squares mean between‐group difference [standard error]: 9.8 [3.5], p = 0.0127). TTR and 10MWR mean times were stable, representing clinically meaningful differences versus ECs. An increased divergence in NSAA total score from 5‐year natural history predictions favoring gene therapy was also seen. Discussion: Findings support the long‐term, manageable safety profile of delandistrogene moxeparvovec in ambulatory patients with appropriate monitoring and demonstrate stabilization or delayed disease progression with treatment compared with matched untreated ECs.


  • Open Access

    Quantitative Measurement of Glycosylated ⍺-Dystroglycan as a Biomarker for Disease Severity in Limb-Girdle Muscular Dystrophy Type 2I/R9

    by John Vissing, Tahseen Mozaffar, Nicholas E. Johnson, Katherine D. Mathews, Matthew P. Wicklund, Conrad Weihl, Doris G. Leung, Jeffrey M. Statland, Peter B. Kang, Carla D. Zingariello, et al.

    Limb-girdle muscular dystrophy type 2I (LGMD2I/R9) is caused by biallelic variants in the gene for Fukutin-related protein (FKRP), an enzyme required for proper glycosylation of α-dystroglycan (⍺DG), a critical structural protein of the dystrophin glycoprotein complex. Hypoglycosylation of αDG results in impaired function of αDG, which in turn leads to chronic myocyte injury and muscular dystrophy. The “Biomarker Development in LGMD2I/R9” (MLB-01-001) natural history study explored glycosylated ⍺DG as a muscle biomarker for LGMD2I/R9 to support clinical trial design for the development of potential therapeutics. MLB-01-001 was a prospective, 12-month observational study of clinically affected participants 10–65 years of age with genetically confirmed LGMD2I/R9 at 11 academic centers in the United States and Denmark. Tibialis anterior (TA) muscle biopsies were obtained at baseline, month 6, month 9, and/or month 12 and measured for glycosylated ⍺DG levels relative to that of an unaffected human control using a validated, quantitative western blot assay. Of 96 participants enrolled, 71 participants underwent at least 1 TA biopsy (54 homozygous for the c.826C>A variant and 17 with other FKRP genotypes). Participants who were homozygous for the c.826C>A variant tended to be older, to be composed of a higher percentage of females, to have had less time since diagnosis, and to be composed of a greater percentage of ambulatory participants than those who had other FKRP genotypes. Glycosylated ⍺DG levels were consistently lower in LGMD2I/R9 participants than in the control at baseline (median 8.5% of control, interquartile range [IQR] 10.8%) and reflected disease severity by genotype, with c.826C>A homozygotes showing higher median glycosylated ⍺DG levels (10.5% of control, IQR 10.9%, n = 54) than participants with other FKRP genotypes (4.6% of control, IQR 4.3%, n = 17). Glycosylated αDG levels remained stable over 6–12 months. Glycosylated ⍺DG was consistently lower in participants with LGMD2I/R9 than in the unaffected control, reflected disease severity by genotype, and remained stable over 6–12 months, suggesting that it may be an appropriate biomarker for assessing the effect of potential therapies for LGMD2I/R9. ClinicalTrials.gov ID NCT04202627, first posted 17 Dec 2019.


  • Open Access

    Motor Function in Limb-Girdle Muscular Dystrophy R1/2A

    by Meredith K. James, Megan A. Iammarino, Natalie F. Reash, Christopher L. Steiner, Audrey B. Knight, Melissa A. Smith, Dionne Moat, Jassi Michell-Sodhi, Karen S.W. Wong, Emma Grover, et al.

    Limb-girdle muscular dystrophy (LGMD) type R1/2A, calpain-3-related, is a rare, autosomal recessive disorder caused by pathogenic variants in the CAPN3 gene. LGMDR1/2A causes progressive weakness of upper and lower limbs, leading to difficulty walking and use of arms for overhead activities. The rate of progression of LGMDR1/2A is unknown because of the limited number of published cohorts and the lack of validated outcome measures. Quantifying the natural history of LGMDR1/2A using standardized outcome measures is critical for understanding the rate of disease progression and improving clinical care and clinical trial readiness. The aim of this cross-sectional study was to evaluate the suitability of the North Star Assessment for limb-girdle type muscular dystrophies (NSAD), 100-meter timed test (100MTT), and Performance of Upper Limb 2.0 (PUL) as outcome measures for quantifying disease presentation and progression in individuals with LGMDR1/2A. Ninety-two individuals were evaluated by physiotherapy teams at Nationwide Children's Hospital and the John Walton Muscular Dystrophy Research Centre. Psychometric analysis of NSAD and PUL was completed using Rasch measurement methods. Descriptive statistics and correlation coefficients explored the relationship among all outcomes. Psychometric analyses demonstrated that NSAD and PUL were valid and appropriate functional outcome measures for ambulant and nonambulant individuals with LGMDR1/2A. The NSAD and 100MTT velocity were highly correlated (Spearman rho Rs(88) = 0.89) The 100MTT was particularly useful for the strongest and asymptomatic cohort. In this largest reported cohort of individuals with LGMDR1/2A, NSAD, PUL, and 100MTT were suitable to quantify functional impact of the disease. International harmonization of outcome measures creates meaningful clinical data to inform clinical management and trial design.


  • Limb-Girdle Muscular Dystrophy Scientific Workshop

    by Matthew P. Wicklund, Lindsay N. Alfano, Nicholas E. Johnson, Peter B. Kang, Peter Marks, Katherine D. Mathews, Jerry R. Mendell, Louise Rodino-Klapac, Douglas Sproule, Nicole Verdun, et al.

    Limb-girdle muscular dystrophy (LGMD) refers to a group of muscular dystrophies that generally result in weakness and loss of limb-girdle muscles, leading to severe disability and early mortality due to cardiac and respiratory complications. Heterogeneity across and within individual LGMD subtypes in addition to variability in progression rates presents significant challenges to traditional drug development approaches for these diseases. In an effort to discuss these challenges, as well as opportunities in support of advancing drug development for LGMD, on February 8, 2024, The Speak Foundation assembled a multistakeholder group consisting of academic medical experts, patients and caregivers, patient advocacy organizations, senior leaders from the US Food and Drug Administration, and commercial drug developers. This review will provide an overview of the broad range of topics discussed at the workshop, including LGMD pathophysiology, natural history studies, clinical outcomes, patient-focused drug development, surrogate end points, the Accelerated Approval pathway, and future directions for LGMD drug development.


  • Open Access

    Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy

    by Marianela Schiava, Yolande Parkhurst, Matthew Henderson, Tuomo Polvikoski, Manouela V. Valtcheva, Ichizo Nishino, Michio Inoue, Yukako Nishimori, Yoshihiko Saito, Tanya Stojkovic, et al.

    Valosin Containing Protein-associated multisystem proteinopathy (VCP-MSP) is a progressive, autosomal dominant disorder caused by pathogenic variants in the VCP gene, resulting in a heterogeneous clinical presentation. Muscle biopsy findings are characteristic but not pathognomonic. This study aimed to comprehensively analyse VCP-related myopathology and explore correlations with clinical phenotypes, genetic variants, and disease progression. Muscle biopsy images and data were collected retrospectively from adults (≥18 years) with pathogenic or likely pathogenic VCP variants enrolled in the VCP Multicentre International Study. Biopsy data were standardized using the “Common Data Elements for Muscle Biopsy Reporting.” Variations in biopsy findings were analysed by biopsy site, time from disease onset, the four most common VCP variants, and clinical phenotypes. A total of 112 muscle biopsies were included. Most individuals were male (66.0%). The mean age at biopsy was 53.3 years (SD 10.0), with a mean disease duration of 6.5 years (SD 4.5). The most frequent VCP variant was c.464G>A (p.Arg155His) (18.8%). The top clinical phenotypes were isolated myopathy (37.5%), myopathy with Paget disease of bone (17.9%), and myopathy with motor neuron involvement (13.4%). The vastus lateralis was the most common biopsy site (34.8%), and 91% were open biopsies. Histopathologic findings included atrophic fibres (87.5%), rimmed vacuoles (72.3%), endomysial fibrosis (58.0%), and protein aggregates (51.8%), primarily p62 (60.3%) and VCP (36.2%). Degeneration niches with fibrofatty replacement and atrophic fibres were seen in 33.3% of biopsies without frequency differences by clinical phenotypes. There were no differences in biopsy findings among the 4 most common VCP gene variants, except for the absence of degeneration niches in muscle biopsies of 12 patients with c.277C>T (p.Arg93Cys). MRI data from 30 patients showed fat pockets corresponding to these niches and STIR hyperintensity correlated with inflammatory infiltrates in 42.9%. Concordance between clinical phenotype, biopsy, and neurophysiology was observed in only 49.4% of cases, indicating significant heterogeneity. VCP-MSP muscle biopsies consistently show myopathic or mixed patterns with rimmed vacuoles and p62/VCP-positive inclusions, regardless of clinical phenotype, age, or progression. Some lack vacuoles, challenging diagnosis. Discrepancies between clinical, neurophysiology, and biopsy findings should prompt consideration of VCP-MSP to improve detection and management.


  • Open Access

    A prospective observational study assessing the functional disease progression of LGMDR4, betasarcoglycan-related limb girdle muscular dystrophy

    by Megan A Iammarino, Natalie F Reash, Kiana Shannon, Maggie Dugan, Kelly Lehman, Alayne Meyers, Jerry R Mendell, Lindsay N Alfano, Linda P Lowes

    Introduction: Limb-girdle muscular dystrophy (LGMD) R4, betasarcoglycanopathy, is a progressive muscle disease that frequently presents in childhood and results in loss of ambulation around 20 years of age. With interventional trials on the horizon it is essential to document functional disease progression using standardized performance outcome assessments (PerfO). Methods: We present a prospective longitudinal observational study of individuals recruited through both Nationwide Children's Hospital neuromuscular clinics and through outreach events held in an area with a high incidence of Founder variant (c.452C > G). PerfOs included the NorthStar Assessment for limb-girdle dystrophies (NSAD), Performance of Upper Limb (PUL), timed function tests, and spirometry, as appropriate. Results: Forty-six individuals enrolled (aged 3–55 years) with 22 (55%) ambulant. Most PerfOs quantified change over time. We found heterogeneity of functional abilities at all ages. In our cohort, children's performance improved until around age 7, followed by a plateau until around 10–12 years. The ability to rise from the floor was the first milestone lost and was unable to be completed by anyone who took longer than 7.7 s on the 10-meter. Further, performance on select PerfOs were related to skills of functional independence, informing clinical care and data driven trial design. Conclusion: There is a great deal of functional heterogeneity. The selected PerfOs measured motor function and disease progression in individuals with LGMDR4, for the benefit of both data driven clinical management and clinical trial design.


  • Open Access

    Validity and Reliability of Clinical and Patient‐Reported Outcomes in Multisystem Proteinopathy 1

    by Lindsay N. Alfano, Megan A. Iammarino, Natalie F. Reash, Linda P. Lowes, Lindsay Pietruszewski, Kathleen Adderley, Lauren Humphrey, Audrey B. Knight, Christopher L. Steiner, Melissa A. Smith, et al.

    Objective: Valosin‐containing protein (VCP)‐associated multisystem proteinopathy 1 (MSP1) is caused by variants in the VCP gene. MSP1 results in various phenotypes including progressive myopathy, Paget's disease of bone, frontotemporal dementia, amyotrophic lateral sclerosis, and parkinsonism, among others. Our study aimed to validate functional clinical outcome assessments (COA) and patient‐reported outcomes (PRO) to inform clinical care practices and future clinical trial design. In addition, we evaluated the test–retest reliability of these COAs within clinics and remote environments.Methods: Patients completed a battery of COA and PRO across a 2‐day traditional onsite visit and a 2‐day remote visit within their home environment. All COA and PRO deemed safe and feasible to complete based on participants' level of function and/or home environment were collected at each visit.Results: Forty‐six total patients enrolled in our study, 34 in our full study and 12 in an expanded remote‐only cohort. Functional COA measured decline over reported disease duration in this cross‐sectional group and significantly correlated with PRO (rho > 0.5, p < 0.001). Differences in lower and upper extremity involvement were noted across variant groups. Performance of functional COA was reliable and safe within and across onsite and remote testing environments (ICC > 0.7, p < 0.001).Interpretation: Functional COA and PRO are valid and reliable to measure abilities in participants with MSP1. Testing can be completed reliably within the home, which could expand equitable access to clinical care and/or future clinical trial participation. Prospective longitudinal data collection is ongoing to understand outcome sensitivity and meaningful change over time.

  • Open Access

    Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study

    by Stephanie M. Hunn, Lindsay N. Alfano, Aileen Jones, Amanda Butler, Linda P. Lowes, Megan A. Iammarino, Natalie F. Reash, Lindsay Pietruszewski, Sandhya Sasidharan, Melissa Currence, et al.

    Objective: Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials.Methods: Through the Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP‐LGMD) Consortium, 42 subjects with LGMDR1 were enrolled in a 12‐month natural history study across 11 international sites. Each subject completed a battery of clinical outcome assessments (COA), including the North Star Assessment for Limb Girdle‐Type Dystrophies (NSAD), 10‐m walk/run, and Performance of the Upper Limb (PUL), in addition to several patient‐reported outcome measures (PROM).Results: In this baseline cross‐sectional analysis, significant correlations were found between COAs and PROMs, with significant differences in the performance of assessments based on subjects' ambulatory status and genetic variant classification.Interpretation: The study has determined that the NSAD and other assessments are valid and reliable measures for quantifying the level of disease impairment in individuals with LGMDR1.


  • Open Access

    Psychometric evaluation of the PROMIS parent proxy mobility item bank for use in Duchenne muscular dystrophy

    by Linda Pax Lowes, Corinne M. Le Reun, Lindsay N. Alfano, Natalie F. Reash, Megan A. Iammarino, Shivangi Patel, Ivana F. Audhya

    Aim: To evaluate the psychometric properties and measurement quality of the Patient‐Reported Outcomes Measurement Information System Parent Proxy (PROMIS PP) Mobility item bank (v1.0, 23 items) for children with Duchenne muscular dystrophy (DMD), through Rasch statistical analysis.Method: De‐identified PROMIS PP Mobility items were completed by the caregivers of male patients with DMD, aged 4 to 12 years, as part of standard clinical care at the Nationwide Children's Hospital clinic; data were mined retrospectively from electronic health records. Rasch analysis was used to assess the internal functioning of the measure and items.Results: Overall, 151 observations were available for the Rasch analysis, equally split between patients aged 4 to 7 years and 8 to 12 years. After removing clinically irrelevant items and regrouping response options for specific items, the resulting 19‐item measure demonstrated overall good fit to Rasch model expectations and the ability to discriminate between respondents with different mobility levels (Person Separation Index = 0.95, excellent reliability).Interpretation: The customized PROMIS PP Mobility measure demonstrated good fit and may be a reliable option for mobility assessment in children with DMD. Rasch analysis can be used by other researchers to improve the sensitivity of patient‐reported outcomes in their field of interest.